<SEC-DOCUMENT>0001104659-19-028985.txt : 20190513
<SEC-HEADER>0001104659-19-028985.hdr.sgml : 20190513
<ACCEPTANCE-DATETIME>20190513171209
ACCESSION NUMBER:		0001104659-19-028985
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190510
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190513
DATE AS OF CHANGE:		20190513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		19819326

	BUSINESS ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a19-9748_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT PURSUANT TO<br> SECTION&nbsp;13 OR 15(d)&nbsp;OF THE<br> SECURITIES EXCHANGE ACT OF 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported): <b>May&nbsp;10, 2019</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="162" height="54" src="g97481bai001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">AMICUS THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as Specified in Its Charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">001-33497</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">71-0869350</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other   Jurisdiction<br>   of Incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission<br>   File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer<br>   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1 Cedar Brook Drive, Cranbury, NJ&#160; 08512</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of Principal Executive Offices, and Zip Code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">609-662-2000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s Telephone Number,&nbsp;Including Area Code</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or Former Address, if Changed Since Last Report)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 46.7pt;text-indent:-19.65pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 46.7pt;text-indent:-19.65pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 46.7pt;text-indent:-19.65pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 46.7pt;text-indent:-19.65pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emerging growth company </font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. </font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of the Act:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Title&nbsp;of&nbsp;each&nbsp;class</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Trading&nbsp;Symbol(s)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Name&nbsp;of&nbsp;each&nbsp;exchange&nbsp;on&nbsp;which&nbsp;registered</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common Stock, $0.01 Par   Value</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FOLD</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NASDAQ</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109760\19-9748-1\task9357840\9748-1-ba.htm',USER='109760',CD='May 14 02:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;10, 2019, the Board of Directors (the &#147;Board&#148;) of Amicus Therapeutics,&nbsp;Inc. (the &#147;Company&#148;), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Burke W. Whitman as a member of the Board, effective June&nbsp;27, 2019. Mr.&nbsp;Whitman will serve as a Class&nbsp;II director, with an initial term expiring at the annual meeting of stockholders in 2021. Mr.&nbsp;Whitman is expected to serve on both the Audit and Compliance Committee and Nominating and Corporate Governance Committee of the Board.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board determined that Mr.&nbsp;Whitman qualifies as an independent director under the director independence standards set forth by the U.S. Securities and Exchange Commission and applicable NASDAQ Marketplace Rules.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with his appointment and as approved by the Board, Mr.&nbsp;Whitman will receive a new director grant of non-qualified options and RSUs worth $400,000, with half of the value assigned to non-qualified stock options and half of the value assigned to RSUs, that will vest over a period of four years, with 25% vesting on the first anniversary of the start date and monthly vesting thereafter.&nbsp; Beginning in 2020, Mr.&nbsp;Whitman will then receive an annual equity grant of non-qualified options and RSUs worth $225,000, with 2/3 of the value assigned to non-qualified stock options and 1/3 of the value assigned to RSUs. Mr.&nbsp;Whitman will also receive $47,500 per year for service as a Board member, $10,000 per year for service as a member of the Audit and Compliance Committee and $7,500 per year for service as a member of the Nominating and Corporate Governance Committee.</font> There are no arrangements or understandings between Mr.&nbsp;Whitman and any other person pursuant to which Mr.&nbsp;Whitman was appointed as a director. There are no transactions involving Mr.&nbsp;Whitman that are reportable under Item 404(a)&nbsp;of Regulation S-K.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 7.01</font></b>&nbsp;-&nbsp;<b>Regulation FD Disclosure.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;13, 2019, the Company issued a press release announcing the appointment of Mr.&nbsp;Whitman to the Board.&#160; A copy of the press release is filed as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K and is incorporated herein by reference.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information furnished pursuant to this Item 7.01, including Exhibit&nbsp;99.1, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<u>Exchange Act</u>&#148;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01 - Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Exhibits:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a19-9748_1ex99d1.htm#Exhibit99_1_010259" title="Click to goto ">Press Release dated May&nbsp;13, 2019</a></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_010959_4179"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109760\19-9748-1\task9357840\9748-1-ba.htm',USER='109760',CD='May 14 02:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 3.6in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AMICUS   THERAPEUTICS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;13, 2019</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Ellen S. Rosenberg</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:   Ellen S. Rosenberg</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:   Chief Legal Officer and Corporate Secretary</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_011359_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109760\19-9748-1\task9357840\9748-1-ba.htm',USER='109760',CD='May 14 02:02 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a19-9748_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1<a name="Exhibit99_1_010259"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="143" height="48" src="g97481mmi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CRANBURY, N.J., May&nbsp;13, 2019</font></b> &#151; Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr.&nbsp;Whitman is a proven leader of corporate and military organizations.&#160; He has served as a corporate CEO, CFO and board member of multiple publicly-traded and Fortune 500 healthcare service companies, as well as the commanding general of the 4th Marine Division and the commander of Marine Forces Reserve.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics,&nbsp;Inc., stated, &#147;On behalf of our Board of Directors,&nbsp;I am pleased to announce Burke Whitman&#146;s appointment to the Amicus Board. Burke brings tremendous experience in leadership, strategy, operations and organizational effectiveness in both the military and in the healthcare fields. His remarkable service to our nation is humbling and his extensive high integrity executive leadership in healthcare and his boardroom experience will add much to our mission at Amicus for patients and for shareholders. Burke&#146;s appointment complements our existing strong group of directors and senior leaders as we continue to build one of the world&#146;s leading global biotechnology companies in rare metabolic diseases.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Currently a major general in the United States Marine Corps Reserve, Mr.&nbsp;Whitman has held various roles of increasing responsibility in the Marine Corps since 2008, and will complete his uniformed service in 2019. A veteran of multiple combat deployments, his decorations include a Defense Superior Service Medal, two Legion of Merit Medals, a Bronze Star Medal, two Combat Action Ribbons, and a Presidential Unit Citation.&#160; Concurrently, since 2018 he serves as a member of the board of directors of Omega Healthcare Investors,&nbsp;Inc. (NYSE: OHI).&#160; Prior to returning to active military service in 2008, Mr.&nbsp;Whitman served as the Chief Executive Officer and as a director of Health Management Associates,&nbsp;Inc. (formerly NYSE: HMA), an owner and operator of acute care hospitals, where he was named a Best CEO by <i>Institutional Investor</i> magazine in 2008.&#160; From 1998 to 2005, Mr.&nbsp;Whitman served as the Chief Financial Officer of Triad Hospitals,&nbsp;Inc. (formerly NYSE: TRI), an owner and operator of hospitals, where he was twice named a Best CFO by <i>Institutional Investor</i> magazine.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr.&nbsp;Whitman has served on the board of directors of the Toys for Tots Foundation as chairman of the investment committee, and on the board of directors of the Federation of American Hospitals as chairman of the audit committee.&#160; He is a founder of the National Museum of the Marine Corps, and has served on the board of advisors of Marine Corps University.&#160; Currently he serves on the U.S. Reserve Forces Policy Board as an advisor to the Secretary of Defense, and on the board of trustees of the Lovett School in Atlanta. Mr.&nbsp;Whitman received a Master of Business Administration from Harvard Business School, a Master of Strategic Studies from the U.S. Army War College, and a Bachelor of Arts from Dartmouth College.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Amicus is at the forefront of science and innovation, with a unique dedication to people living with rare diseases. The Amicus focus on its mission for patients, its remarkable commitment and vision to become one of the world&#146;s most significant biotechnology companies are what drew me to this opportunity.&#160; I am thrilled to be joining the Board at such an exciting time in the Company&#146;s growth,&#148; said Mr.&nbsp;Whitman. &#147;I look forward to advancing the company&#146;s mission to develop groundbreaking new medicines and hopefully one day cures for life-threatening conditions.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Amicus Therapeutics</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company&#146;s website at www.amicusrx.com, and follow on Twitter and LinkedIn.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONTACTS:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investors:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amicus Therapeutics</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sara Pellegrino,&nbsp;IRC</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,&nbsp;Investor Relations&nbsp;&amp; Corporate Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">spellegrino@amicusrx.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(609) 662-5044</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C905656\19-9748-1\task9357676\9748-1-mm.htm',USER='C905656',CD='May 14 01:10 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amicus Therapeutics</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Marco Winkler</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">mwinkler@amicusrx.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(609) 662-2798</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FOLD&#150;G</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C905656\19-9748-1\task9357676\9748-1-mm.htm',USER='C905656',CD='May 14 01:10 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g97481mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97481mmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  P (\# 2(  A$! Q$!_\0
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M$RK8:<;^S5[EKX2V3)9:A>L.))%B4_[H)/\ Z$*]#JGI.EV^C:9#8VBD11#
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'1E?5Z'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g97481bai001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97481bai001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  V *(# 2(  A$! Q$!_\0
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MZ%CYI558YXP#GHO7FKA#GERWL3.7(KV.HHIL>\QKY@ ? W =,]Z=4%!1110
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MB+1 #TC<_A\E*E&,W2;2UOT[!4E*"J)-Z6.D\:>+)/#6EVZVX5[VY'REQD*
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M!?"26)H=[HA=\Y7!..15S6+*^GN=>-G'('FL84C9>-Y!?<JGUP?U%/V:VO\
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8Y)HHHN!-1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
